Frequency of Hypersensitivity Reactıons to Chemotherapeutic Agents in Children With Cancer

2019 ◽  
Author(s):  
Osman Ozturk
Keyword(s):  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions ◽  
Children With Cancer

scholarly journals Successful olaparib desensitization using a novel one-day protocol

2020 ◽  
Vol 16 (1) ◽  
Author(s):  
Rongbo Zhu ◽  
Stephen Welch ◽  
Hannah Roberts
Keyword(s):  
Adverse Reactions ◽  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions ◽  
Immediate Hypersensitivity ◽  
Case Presentation ◽  
Tablet Form ◽  
Desensitization Protocol ◽  
Ige Mediated ◽  
Loss Of Tolerance

Abstract Background Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with olaparib. Case presentation We report a 58-year-old female with immediate, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day novel desensitization protocol to olaparib. Following desensitization, the patient was successfully transitioned from olaparib capsules to tablets with no loss of tolerance. Conclusions To our knowledge, this is the first reported case of successful olaparib desensitization using a novel 1-day desensitization protocol, and will contribute to drug allergy knowledge, in an area where robust data is lacking. This case demonstrates the important role for drug desensitization in patients with immediate hypersensitivity reactions to chemotherapeutic agents. Furthermore, as olaparib capsules are being phased out in favour of olaparib tablets, we provide a clear case that transitioning from capsule to tablet form did not cause a loss of tolerance.

scholarly journals Biomarkers Associated with Hypersensitivity Reactions to Chemotherapeutic Agents.

2020 ◽  
Vol 145 (2) ◽  
pp. AB100
Author(s):  
F. Javier Fernandez ◽  
Teodorikez Jimenez Rodriguez ◽  
Maria Ruano-Zaragoza ◽  
Purificación Gonzalez-Delgado ◽  
Victor Soriano-Gomis
Keyword(s):  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions

Immediate reaction to ibrutinib amenable to oral desensitization

2021 ◽  
pp. 107815522110046
Author(s):  
Neelam A Phadke ◽  
Samantha O Luk ◽  
Ephraim P Hochberg ◽  
Aleena Banerji
Keyword(s):  
Maculopapular Rash ◽  
Chemotherapeutic Agents ◽  
Lymphocytic Leukemia ◽  
Hypersensitivity Reactions ◽  
First Line ◽  
Management Guidelines ◽  
Cutaneous Hypersensitivity ◽  
Ige Mediated ◽  
To Receive ◽  
Oral Desensitization

Introduction Although up to half of patients receiving chemotherapeutic agents develop hypersensitivity reactions to the same, desensitization protocols can induce temporary tolerance to allow patients to continue to receive first-line treatment. Approximately 25% of patients develop cutaneous hypersensitivity reactions to ibrutinib, but there are no published management guidelines. Case report We describe the case of a 71-year-old woman with chronic lymphocytic leukemia who developed a delayed maculopapular rash with lip tingling and swelling following ibrutinib therapy. Management and outcome We performed a novel 11-step desensitization procedure to ibrutinib allowing us to successfully induce tolerance against IgE-mediated symptoms in this patient. Discussion As indications for ibrutinib use expand and more patients present with IgE-mediated symptoms, we expect that this protocol will provide benefit for many such patients.

Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer

2013 ◽  
Vol 69 (10) ◽  
pp. 1739-1746 ◽  
Author(s):  
Antonio Ruggiero ◽  
Silvia Triarico ◽  
Giovanna Trombatore ◽  
Andrea Battista ◽  
Fabiola Dell’Acqua ◽  
...  
Keyword(s):  
Clinical Features ◽  
Hypersensitivity Reactions ◽  
Chemotherapeutic Drugs ◽  
Children With Cancer

scholarly journals Hypersensitivity Reactions to Platinum Agents and Taxanes

2021 ◽  
Author(s):  
Lulu R. Tsao ◽  
Fernanda D. Young ◽  
Iris M. Otani ◽  
Mariana C. Castells
Keyword(s):  
Clinical Presentation ◽  
Skin Testing ◽  
Chemotherapeutic Agents ◽  
Hypersensitivity Reactions ◽  
First Line ◽  
Multiple Cycles ◽  
Desensitization Protocol ◽  
Drug Challenge ◽  
Chemotherapy Agents ◽  
Platinum Agents

AbstractHypersensitivity reactions (HSRs) to chemotherapy agents can present a serious challenge to treating patients with preferred or first-line therapies. Allergic reactions through an immunologic mechanism have been established for platinum and taxane agents, which are used to treat a wide variety of cancers including gynecologic cancers. Platin HSRs typically occur after multiple cycles of chemotherapy, reflecting the development of drug IgE sensitization, while taxane HSRs often occur on first or second exposure. Despite observed differences between platin and taxane HSRs, drug desensitization has been an effective method to reintroduce both chemotherapeutic agents safely. Skin testing is the primary diagnostic tool used to risk-stratify patients after initial HSRs, with more widespread use for platinum agents than taxanes. Different practices exist around the use of skin testing, drug challenge, and choice of desensitization protocol. Here, we review the epidemiology, mechanism, and clinical presentation of HSRs to platinum and taxane agents, as well as key controversies in their evaluation and management.

scholarly journals Selenium in the Prevention of Anthracycline-Induced Cardiac Toxicity in Children with Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Nurdan Tacyildiz ◽  
Derya Ozyoruk ◽  
Guzin Ozelci Kavas ◽  
Gulsan Yavuz ◽  
Emel Unal ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Plasma Level ◽  
Protective Effect ◽  
Pediatric Cancer ◽  
Cardiac Toxicity ◽  
Chemotherapeutic Agents ◽  
Children With Cancer ◽  
Term Adverse Effect ◽  
Pediatric Cancer Patients

High cumulative doses of anthracyclines (300–500 mg/m2) used in the treatment of children with cancer may result in cardiotoxicity, a major long-term adverse effect that limits clinical usefulness of this class of chemotherapeutic agents. We assessed anthracycline-induced cardiotoxicity by measuring Pro-BNP levels and echocardiographic (ECHO) findings and investigated potential protective effect of selenium (Se) supplementation in a group of pediatric cancer patients. Plasma level of Pro-BNP was measured, and ECHO was performed in 67 patients (45 boys, 22 girls; ages 2–18 years; median age 12 years) after they completed anthracycline-containing chemotherapy. Serum Se level was measured in 37 patients. Eleven patients had high Pro-BNP levels and/or cardiac failure with Pro-BNP levels of 10–8,022 pg/mL (median 226.3 pg/mL; laboratory normal level is less than 120 pg/mL). Serum Se levels were low (20–129 mcg/L, median 62 mcg/L) in ten of these eleven patients. Eight of 10 patients with low Se and high Pro-BNP levels were supplemented with Se 100 mcg/day for a period of 4–33 months (median 6 months) which resulted in improvement in Pro-BNP and/or ECHO findings. These results suggest that Se supplementation may have a role in protection against anthracycline-induced cardiac toxicity.

scholarly journals Oral Involvements of Hypersensitivity Reactions to ChemotherapyDrugs in Immunocompromised Child Patient: A Case Report

2017 ◽  
Vol 1 ◽  
Author(s):  
Agam Ferry Erwana ◽  
Irna Sufiawati
Keyword(s):  
Case Report ◽  
Acute Otitis Media ◽  
Mitotic Rate ◽  
Chemotherapeutic Agents ◽  
Lymphocytic Leukemia ◽  
Comprehensive Treatment ◽  
Type I ◽  
Hypersensitivity Reactions ◽  
Good Treatment Outcome ◽  
Almost All

<p class="AbstractContent"><strong>Background:</strong> Hypersensitivity reactions (HSRs) may occur in children with cancer during the use of almost all chemotherapeutic drugs, commonly present with mild/moderate to severe clinical patterns.</p><p class="AbstractContent"><strong>Case report:</strong> A 7-year-old, male patient, was referred from the RSUP Hasan Sadikin Pediatric Department, with the diagnosis of Acute Lymphocytic Leukemia (ALL), acute otitis media and Toxic Epidermal Necrolysis (TEN) ec susp/ metrotreksat ec susp/ leucovorine. The patient was diagnosed with oral involvement related to anemia and TEN. Lesions of reddish black crusts manifested on upper and lower lips, and multiple red macules in labial and buccal mucosas. Oral lesions showed significant improvement after administration of comprehensive treatment including corticosteroid mixed ointment, antimitotic oral suspension and multivitamin.</p><p class="AbstractContent"><strong>Discussion:</strong> The mechanisms responsible for most HSRs, including drug-related are not known, as they have generally not been evaluated. Most reactions are of the type I category in the Gell and Coombs classification, but there also are instances of types II, III, and IV reactions caused by many of the antineoplastic agents. Oral involvements in children due to hypersensitivity reactions are likely to occurred because they are more susceptible to stomatotoxic effects of chemotherapeutic agents, possibly related to a higher epithelial mitotic rate.</p><strong>Conclusion:</strong> Knowledge of the different clinical presentations of chemotherapeutic agent’s hypersensitivity reactions ‘oral involvements can help to ensure a good treatment outcome, to improve the quality of patient care and to reduce healthcare costs.

Sign in / Sign up

Export Citation Format

Share Document